Switch to: References

Add citations

You must login to add citations.
  1. Risk Communication for Nanobiotechnology: To Whom, About What, and Why?Susanna Hornig Priest - 2009 - Journal of Law, Medicine and Ethics 37 (4):759-769.
    Regulatory oversight and public communication are intimately intertwined. Oversight failures quickly galvanize media and public attention. In addition, regulations sometimes require that risks and uncertainties be included in communication efforts aimed at non-experts outside of the regulatory and policy communities — whether in obtaining informed consent for novel medical treatments; by including risk information on drug labels, in drug advertisements, or on chemicals used in the workplace; in providing nutritional information on food packages; or by opening environmental impact assessments to (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  • Risk Communication for Nanobiotechnology: To Whom, about What, and Why?Susanna Hornig Priest - 2009 - Journal of Law, Medicine and Ethics 37 (4):759-769.
    Regulatory oversight and public communication are intimately intertwined. Oversight failures, both actual and perceived, quickly galvanize attention from both the media and the public, as has occasionally happened in all of the historical cases with which this symposium is concerned — gene therapy, workplace chemicals, drugs and devices, and genetically modified organisms, especially those used as foods. Some developments, such as GMOs, seem to have more cultural significance or “cultural resonance” than others and are especially likely to garner public attention. (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  • Commentary: Public Outreach by the FDA: Evaluating Oversight of Human Drugs and Medical Devices.Mark S. Frankel - 2009 - Journal of Law, Medicine and Ethics 37 (4):625-628.
    As nanotechnology emerges as an important public policy issue, the FDA's relationship with society is about to be tested. Most would agree that fostering public input will be critical to developing effective public policy for nanotechnology. Yet, it will not be easy. Low public confidence in the FDA, the general lack of knowledge about nanotechnology among ordinary Americans, and the way in which the “average” citizen obtains and evaluates knowledge about a public policy issue all pose serious challenges to any (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Commentary: Public Outreach by the FDA: Evaluating Oversight of Human Drugs and Medical Devices.Mark S. Frankel - 2009 - Journal of Law, Medicine and Ethics 37 (4):625-628.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Commentary: Evaluating Oversight of Human Drugs and Medical Devices.Susan Bartlett Foote - 2009 - Journal of Law, Medicine and Ethics 37 (4):629-632.
    This article seeks to provide insights into appropriate FDA oversight of nanotechnology. This commentary identifies limitations in the methodology employed and concludes that the analysis would be stronger with a more in-depth institutional dimension based on administrative law and political science research.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Commentary: Evaluating Oversight of Human Drugs and Medical Devices.Susan Bartlett Foote - 2009 - Journal of Law, Medicine and Ethics 37 (4):629-632.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Adding to the Mix: Integrating ELSI into a National Nanoscale Science and Technology Center.David J. Bjornstad & Amy K. Wolfe - 2011 - Science and Engineering Ethics 17 (4):743-760.
    This paper describes issues associated with integrating the study of Ethical, Legal and Social Issues (ELSI) into ongoing scientific and technical research and describes an approach adopted by the authors for their own work with the center for nanophase materials sciences (CNMS) at the Oak Ridge national laboratory (ORNL). Four key questions are considered: (a) What is ELSI and how should it identify and address topics of interest for the CNMS? (b) What advantages accrue to incorporating ELSI into the CNMS? (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   6 citations